T2 Biosystems, Inc. provided revenue guidance for the year 2023. For the year, Company now expects total sepsis and related product revenue of $9.5 million to $10.5 million, representing growth of 13% to 25%, compared to $8.4 million in 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.06 USD | +2.22% | -16.50% | -19.36% |
15/05 | Sector Update: Health Care Stocks Advance Late Wednesday Afternoon | MT |
15/05 | T2 Biosystems Shares Rise After CRG Servicing Ups Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.36% | 7.61Cr | |
+7.87% | 22TCr | |
+11.83% | 19TCr | |
+18.87% | 14TCr | |
+30.03% | 11TCr | |
+2.32% | 6.52TCr | |
+14.15% | 5.3TCr | |
+2.68% | 5.03TCr | |
+6.60% | 4.42TCr | |
+1.85% | 3.64TCr |
- Stock Market
- Equities
- TTOO Stock
- News T2 Biosystems, Inc.
- T2 Biosystems, Inc. Provides Revenue Guidance for the Year 2023